Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 4/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25221573 | 0.90 | RORC (0.41) | CYP17A1RORCHDAC1KCNQ4KCNQ5 | |
| SCHEMBL26170484 | 0.85 | CYP17A1 (0.48) | CYP17A1RORCHDAC1KCNQ4KCNQ5 | |
| SCHEMBL25214971 | 0.84 | CYP17A1 (0.46) | CYP17A1RORCHDAC1KCNQ4KCNQ5 | |
| SCHEMBL25254806 | 0.82 | HDAC2 (0.58) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL25218254 | 0.81 | HDAC1 (0.45) | CYP17A1RORCHDAC1KCNQ4KCNQ5 | |
| SCHEMBL25255025 | 0.81 | CYP17A1 (0.43) | CYP17A1RORCHDAC1KCNQ4KCNQ5 | |
| SCHEMBL25211166 | 0.81 | CYP17A1 (0.43) | CYP17A1RORCHDAC1KCNQ4KCNQ5 | |
| SCHEMBL25256259 | 0.81 | CYP17A1 (0.43) | CYP17A1RORCHDAC1KCNQ4KCNQ5 | |
| SCHEMBL25224795 | 0.80 | CYP17A1 (0.45) | CYP17A1HDAC1KCNQ4KCNQ5HDAC2 | |
| SCHEMBL1705492 | 0.80 | HDAC1 (0.51) | CYP17A1HDAC1KCNQ4KCNQ5HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | CYP17A1 1294/4885RORC 663/4885HDAC1 1/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | CYP17A1 657/4885RORC 699/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.